IP Library Granted Patent US 9,415,040
Granted Patent B2
US 9,415,040 · App. 14/707,525 · Granted Aug 16, 2016

Inhibition of quorum sensing-mediated processes in bacteria

Inventors: Bonnie Bassler (Princeton, NJ); Lee Swem (San Carlos, CA)
Assignee: The Trustees of Princeton University
A61K31/454A01N41/10A01N43/28A01N43/52A01N43/653A01N43/78A01N43/82A01N43/90A61K31/122A61K31/165A61K31/381A61K31/40A61K31/404A61K31/4184A61K31/4196A61K31/426A61K31/428A61K31/433A61K31/437C07C317/24C07D235/28C07D249/12C07D277/42C07D285/14C07D327/04C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,415,040
App. No.
14/707,525
Granted
Aug 16, 2016
Kind
B2
Abstract

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Claims (13)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant or vehicle and a pharmaceutically-acceptable salt of a small molecule compound whose structure is selected from the group consisting of:

2. The pharmaceutical composition of claim 1 that is a solid dosage form.

3. The pharmaceutical composition of claim 2 that is in the form of capsules, tablets, pills, powders, tinctures or granules.

4. The pharmaceutical composition of claim 2 wherein the salt of the small molecule compound is admixed with at least one inert pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 wherein the carrier is sucrose, lactose, or starch.

6. The pharmaceutical composition of claim 2 that comprises one or more lubricating agents.

7. The pharmaceutical composition of claim 3 that comprises a buffering agent.

8. The pharmaceutical composition of claim 3 that comprises an enteric coating.

9. A method of treatment for infection of a host by gram-negative quorum-sensing bacteria, which comprises administering to the host a therapeutically effective amount of the pharmaceutical composition of claim 1 .

10. The method of claim 9 that is administered orally, nasally, topically or parenterally.

11. The method of claim 9 for treatment for Vibrio bacteria infection.

12. A method of inhibiting infection of Vibrio bacteria in shellfish comprising contacting the bacteria with a small molecule a small molecule compound whose structure is selected from the group consisting of:

in a concentration sufficient to disrupt detection of autoinducer-1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: BASSLER, BONNIE; SWEM, LEE
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 038391/0928 →
CONFIRMATORY LICENSE Recorded Jul 7, 2015
From: PRINCETON UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 036074/0419 →
Continuity (5)
Continuation 14028999 · Sep 17, 2013
Continuation 12995476
Provisional Application 61188310 · Aug 7, 2008
Provisional Application 61130685 · Jun 2, 2008
Related Publication 20150238475A1 · Aug 27, 2015